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Abstract: Chronic subdural haematoma represents a major problem in the neurosurgical 
field concerning population both under and above 75 years old. It is not only a matter of 
prevalence or pure statistics but it embodies true understanding of how the pathology 
affects older patients, their life expectancy and quality when reliable factors are implied 
such as comorbidities, relation with the moment of surgery, the existence of 
anticoagulation therapy, and many more. We target these challenges in a study on 232 
cases of treated chronic subdural haematomas with impact on two major categories - 
those under and above 75 years old in the Neurosurgery Department, County Hospital 
“Pius Branzeu” Timisoara, Romania. 
Key words: antithrombotics, chronic subdural haematoma, midline shift, older 
population 
 
Introduction 
At the basis of chronic subdural 
haematoma (CSH) formation stands multiple 
aetiologies, such as trauma and acute subdural 
haematoma(aSH), spontaneous reasons 
including hydrocephalus, coagulopathies and 
chronic anticoagulation therapy, and 
iatrogenous causes such as a complication of a 
lumbar puncture (LP). 
Among the risk factors involved are: 
predisposing of trauma, alcohol consumption, 
epilepsy, hemorrhage, and other predisposing 
factors such as coagulopathy, antithrombotics, 
high blood pressure, brain atrophy, hygroma 
[2,7,13,22,24] and others. 
Clinical features include: motor deficiency, 
altering of consciousness, intracranial 
hypertension (ICH) syndrome, 
pseudotumoral, pseudodementia syndromes, 
headaches, and progressive speech 
impairment [11]. 
Differential diagnostics comprise of the 
following; stroke, dementia, encephalitis, 
cerebral abscess, tumor, and cerebral 
parasitosis as showed by standard imagistic 
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studies from CT (gold standard) and MRI 
[26,35]. 
The treatment options for CSH are for 
symptomatic cases, midline shift(MLS) with a 
minimum of 5 mm, mass effect, etc., also, 
conservative treatment stands for 
neurologically intact elderly patients on 
antithrombotics - withdrawal of 
antithrombotic medication 7 days prior to the 
surgery - in the case of eligibility for an 
operation, perioperative antibiotherapy 
prophylaxis [5,14,16,17,19,21,33]. 
In respect of the well-established 
techniques used for CSH evacuation these 
include; single “burr-hole” or double “burr-
hole” technique + drainage, craniotomy +/- 
cranioplasty + drainage, subdural evacuating 
port system (SEPS), twist drill craniotomy 
[23], and endoscopy [10,20,27,30,34]. 
In the matter of complications and 
prognostics, the surgical intervention may be 
grafted by complications such as; haematoma 
persistency, pressure pneumocephalus, 
subdural empyema, convulsions, intracerebral 
hemorrhage, and others [8,35]. 
Recurrence of CSH can be early - less than 
3 months postoperative or late - more than 3 
months postoperative [3]. 
Postoperative midline-shift over 5 mm, 
diabetes, preoperative convulsions, over 20 
mm in size of the haematoma, intracranian 
(IC) hypotension, low Glasgow Coma 
Scale(GCS), mixed density of the haematoma 
on the CT-scan, antithrombotic therapy, 
cancer and male population are associated 
with a higher risk of recurrence [19,29,32].  
Aim of the study 
To assess the results of a retrospective 
comparative study of 232 aged-related subjects 
over and under 75 years old with CSH treated 
in the Neurosurgery Dep. Timisoara County 
Hospital between 1st of January 2013 and 30th 
of September 2017. 
 
Materials and methods 
A total of 232 enrolled patients diagnosed 
with CSH from which 181 were male and 51 
were female. Age over 75 yrs.; 70 M and 25 F; 
under 75 yrs.; 111 M and 26 F. Age-related < 
75 yrs. old: 0-10 yrs., 9; 11-20 yrs., 2; 21-30 yrs., 
1; 31-40 yrs., 2; 41-50 yrs., 17; 51-60 yrs., 28 61-
74 yrs., 78. Age-related >75 yrs. old: 75-80 yrs., 
53; 81-85 yrs., 31; 86-90 yrs., 9; 91-95 yrs.:2, 
comprising a single-centre study of the 
Department of Neurosurgery County Hospital 
“Pius Branzeu” Timisoara, Romania. 
Chi Square Test was utilized to predict a 
statistically significant importance of several 
findings in the study. 
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Figure 1 - Sexes and prevalence of patients in respect to cohort 
 
Figure 2 - Age-related No. of patients enrolled under 75 years old 
 
Regarding the data offered by the study, it 
shows that the incidence of CSH increases with 
lower ages in the population studied over 75 
years old as follows: between 75-80 years old 
there were 53 patients included; between 81-85 
years old, 31 patients; between 86-90 years old, 
9 patients and from 91-95 years old, 2 patients.
 
 
Figure 3 - Age-related No. of patients enrolled above 75 years old 
 
Total of patients Patients over 75yrs. 
Patients under 75 
yrs. 
Total 
Male 
Female 
Rural 
Urban 
232 95 137 
181 70 111 
51 25 26 
78 28 50 
154 67 87 
Age Number of patients 
0-10 9
11-20 2
21-30 1
31-40 2
41-50 17
51-60 28
61-74 78
Age Number of patients 
75-80 
81-85 
86-90 
91-95 
53
31
9
2
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Overall, fewer people in the segment 
considering the older than 75 years cohort 
spent between 1 and 3 weeks in hospital in 
comparison to the other studied cohort. Less 
than 1 week in hospital includes 26 patients vs. 
34 in the same 2 groups; between 1-2 weeks it 
was 57 vs. 73 patients, and over 3 weeks in 
hospital there were 7 vs. 8 patients in total.
 
 
Figure 4 - Cohorts in relation to hospitalization 
In addition, they were 44 compared to 74 
people with left-side CSH in the 2 groups, 37 
vs. 40 people with right-side CSH and 14 vs. 23 
having bilateral haematomas.
 
 
Figure 5 - Cohorts in relation with localization of the CSH 
 
Midline shift is another landmark of the 
study that shows the following: 61 vs. 83 
patients did not have any midline shift; 6 vs.10 
patients had 1-5 mm deviation; 15 patients in 
both groups had MLS between 6-10 mm; and 
9 vs.18 had a deviation between 11-15 mm and 
4 vs.11 patients had MLS over 15 mm.
 
 
Figure 6 - Cohorts in relation with MLS 
 
Time of hospitalization Patients over 75 Patients under 75 
Less than 1 week 
1-2 weeks 
2-3 weeks 
Over 3 weeks 
26 34 
57 73 
5 22 
7 8 
Type of CSH Patients
over 75 
Patients 
under 75 
Left 
Right 
Bilateral 
44 74
37 40
14 23
MLS (Midline-shift) Patients over 75 Patients under 75 
0 mm 
1-5 mm 
6-10 mm 
11-15 mm 
over 15 mm 
61 83 
6 10 
15 15 
9 18 
4 11 
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GCS at presentation was recorded for all 
the patients included in the study: GCS 3p was 
seen in 2 vs. 4 patients in the 2 groups studied; 
GCS 4p, 2 vs. 1 patient; GCS 5p, each group 
had 1 patient; GCS6p, none of the 2 groups; 
GCS 7p, 1 vs. 2; GCS 8p, 5 vs. 3; GCS 9p, 4 vs. 
3; GCS 10p, 3 vs. 2; GCS 11p, 0 vs. 1; GCS 12p, 
4 vs. 3; GCS 13p, 10 vs. 7; GCS 14p, 33 vs. 27; 
GCS 15p, 30 vs. 83 in the cohorts. 
 
 
Figure 7 - Cohorts in correlation with GCS at presentation 
 
Clinical features of the CSH were assessed 
as being part of the general findings in this 
study: One-side motor weakness in 61 vs. 73 
cases; dysphasia in 31 vs. 37; headaches in 46 
vs. 86;  
Convulsions in 6 vs. 15 patients; 
paraparesis in 1 vs. 4; tetraparesis 1 vs. 0; 
Unilateral Babinski signs in 22 vs. 23 and 
bilateral Babinski signs in 12 vs. 7 patients 
from the over/under 75 groups.
 
GCS at presentation Patients over 75 Patients under 75 
15 30 83 
14 33 27 
13 10 7 
12 4 3 
11 0 1 
10 3 2 
9 4 3 
8 5 3 
7 1 2 
6 0 0 
5 1 1 
4 2 1 
3 2 4 
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Figure 8 - The 2 groups in relation with clinical features 
 
Figure 9 - Cohorts in relation to radiological modality of exploration 
 
 
Figure 10 - Relationship between associated haematomas and age-related study groups 
 
In the matter of imagistic data, we had 91 
patients scanned with CT in the first group 
and 105 in the second one; 4 had taken an MRI 
scan in the first group vs. 16 in the second one, 
and both investigations were undergone by 16 
of the patients in the second group.
 
Clinical features Patients over 75 Patients under 75 
Hemiparesis 
Dysphasia 
Headaches 
Convulsions 
Paraparesis 
Tetraparesis 
Unilateral Babinski 
Bilateral Babinski  
61 73 
31 37 
46 86 
6 15 
1 4 
1 0 
22 23 
12 7 
Imagistics Patients over 75 Patients under 75 
CT 
MRI 
Both
91 105 
4 16 
0 16 
Associated haematoma Patients over 75 Patients under 75 
Extradural 
Parenchymal 
3 3 
2 1 
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Figure 11 - Associated co-morbidity factors in relation to the 2 populational groups 
 
The associated morbidity and mortality 
factors in the assessment of CSH are amongst 
other important elements in the evaluation of 
age-related evolution of the pathology, 
therefore CRF (Chronic renal failure) was seen 
in 2 vs. 4; Heart failure in 14 vs. 13; Stroke in 
11 vs. 15; Respiratory failure in 12 vs. 9; 
Pneumonia in 7 vs. 9; Afib in 17 vs. 12; 
Ischemic cardiopathy in 27 vs. 18; Sepsis in 
equal parts 4:4; Cancer in 3 vs. 4; High blood 
pressure in 53 vs. 62; Type II diabetes in 14 vs. 
24 and COPD in 1 vs. 5 cases.
 
Figure 12 - Use of antithrombotics in CSH regarding cohorts 
 
Regarding the use of antithrombotics, in 
the first group of patients we found 10 vs. 9 in 
the second one who were on antiplatelet 
therapy and 21 over 75 years old vs. 13 under 
75 years old who took anticoagulants.
 
 
Figure 13 - Time of hospitalization between admission and surgery 
 
Associated co-morbidity Patients over 75 Patients under 75 
Chronic renal failure 
Heart failure 
Stroke 
Respiratory failure 
Pneumonia 
AFib 
Ischaemic cardiopathy 
Sepsis 
Cancer 
High blood pressure 
Type 2 diabetes 
COPD 
2 4 
14 13 
11 15 
12 9 
7 9 
17 12 
27 18 
4 4 
3 4 
53 62 
14 24 
1 5 
Basic antithrombotic 
therapy 
 
Patients over 75 Patients under 75 
Antiplatelet 
Anticoagulants 
10 9 
21 13 
Patients over 75 Patients under 75 
Median days of 
hospitalization from 
admission until surgery 
 
2.30 days 2.99 days 
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Figure 14 - Therapy options in respect of the 2 groups 
 
 
Figure 15 - 89 years old patient CT scan in axial 
plane showing left frontal-parietal CSH and a recent 
ischemic event localized left frontal-pole 
 
Figure 16 - Axial CT scan of a 67 years old patient 
with a 13 cm AP length and a 2.5 cm thick left CSH 
and right midline shift 
 
 
Figure 17 - A 61 years old patient, axial image showing left fronto-parieto-temporal chronic subdural haematoma 
 
Therapy options Patients over 75 Patients under 75 
Surgery 
“Burr-hole” craniectomy 
Craniotomy 
Minimal craniectomy 
CSH kit SEPS 
Conservative 
85 124 
0 2 
2 2 
83 119 
0 1 
10 13 
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Figure 18 - A left isodense CSH with several arias of hypodensity showing re-bleeding phenomenon and a 26 mm 
thickness showing mass effect over the midline shift and almost complete imprinting of the left ventricle 
 
Results 
The study shows the mortality in patients 
older than 75 outnumber those under 75. The 
difference is statistically significant under the 
evaluation of the Chi Square Test (0.0001) thus 
the comatose patient number is higher in the 
cohort representing patients over 75 in 
comparison with the second group, this 
proved not to be statistically significant (Chi 
Square Score 0.125). 
From the two groups, those over 75 were 
treated predominantly in a conservative 
fashion that meant 10.526% vs. 9.489%, also 
without importance in the study 
(value=0.725). 
The number of those over 75 years old on 
antithrombotics is significantly higher than 
younger patients with the same treatment (Chi 
Square Test 0.007). 
Bilateral chronic subdural haematomas 
(bCSH) were rarely observed in the over 75 
years cohort vs. those under, (14.736% and 
16.788%) but this also poses no statistical 
significance (Chi Square Test 0.943) evenly 
quoted by Song DH et al [28] 
From the total number of patients, 54% 
from those under 75 years old, had left 
hemispheric CSH vs 29.1% showing right 
hemispheric involvement. In the second group 
regarding the patients over 75 years old, CSH 
was seen more frequently - 46.3% affecting the 
left side vs 38.9% in the right side. 
In the matter of prevalence of the gender-
dependent population, 81.1% of males and 
18.9% females were under 75 years old in 
comparison to 73.6% of males and 26.3% 
females over 75 years also stated in between 
the values reported in the study by Oh J. et 
al.[24]. 
The improvement of deficits was more 
frequently found in the over 75 years old 
cohort (Chi Square Test 0.010). 
The medium global hospitalization time 
was 10.48 days with a standard deviation of 
7.233 days with a range from 1-49 days. In the 
over 75 year old group the study showed that a 
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total of 26 patients (25.86%) stayed under 1 
week and 7 patients (6.47%) stayed for over 3 
weeks. From that, those staying under 1 week 
comprised 27.37% and those staying over 3 
weeks 7.37%, and in the cohort under 75 years 
old 24.82% under a week and 5.84% over 3 
weeks. 
The second group showed a medium 
hospitalization time of 10.36 days with a 
standard deviation of 6.803 days and in those 
over 75 years old 10.67 days with a 0.839 
standard deviation. 
Mortality was seen in 11.4% in the male 
population and 7.84% in the female 
population from the total of deaths. In our 
study, 33.3% were on antithrombotics either 
antiplatelet or anticoagulation treatment. 
38.8% of the deaths registered in the over 75 
years old cohort were on antithrombotics, but 
less than 16.6% was encountered in those 
under 75. 
 
 
Figure 20 - Outcomes in respect to the clinical features 
 
The average value of MLS was 4.32 mm 
with a standard deviation of 5.772 mm. For the 
first study-group the average MLS was 4.68 
mm (standard deviation 6.043 mm) and for 
the second group the study showed a MLS of 
3.74 mm with a standard deviation of 5.290 
mm. A value of 4.45 mm was showed for the 
patients who overcame the pathology with a 
median standard deviation of 5.797 mm and in 
those who died the prevalence translates to a 
3.21 mm MLS with a median deviation of 
5.548 mm, thus there were no significant 
differences in the two median values 
concerning the 2 study-groups.
 
Clinical features  Total  Patients over 75 yrs old 
Patients under 75 yrs
old 
Hemiparesis  57,758%  64%  53,284% 
Afazia  29%  32,631%  27,007% 
Headaches  56,896%  48,421%  62,773% 
Epilepsy  9,051%  6,315%  10,948% 
Babinsky sgn.  27,586%  35,789%  21,897% 
Unilat.Babinsky  19,396%  23,157%  16,788% 
Bilat.Babinsky  8,189%  12,631%  5,109% 
 
 
 
 
 
Romanian Neurosurgery (2018) XXXII 4: 523 - 537 | 533 
 
 
 
 
 
 
 
 
Figure 21 - Outcomes according to GCS in cohorts 
 
The average value for GCS was 13.34 with 
a standard deviation of 2.823. For those under 
75 years old, the average GCS was 13.66 with a 
standard deviation of 2.648 and for those over 
75 years old the study showed a value of 12.83 
and a mean deviation of 3.027. There is a 
significant difference regarding the value of 
GCS between those who survived and those 
who died. 
From the conservative-treated patients all 
of them had an initial GCS of 14 or 15 with 3 
exceptions: one patient under 75 with a GCS of 
12; one patient over 75 years with a GCS of 3 
and one patient over 75 years with a score of 4. 
Overall, neurological improvement was seen 
in 60% over 75 years old and respectively in 
84.61% under 75. Without any improvement 
there were 30% in the first group and 15.38% 
in the second one. 
In matter of mortality-CSH topography 
relationship, our study showed statistically 
higher rates of mortality for the over 75 years 
group vs. younger ages not only for unilateral 
CSH but also bilateral (Chi Square Test 0.01). 
The evolution of the disease according to 
age group can be summarized as follows: 
Average time of hospitalization from 
admission to surgery was: 2.264 days in the 75-
80 years old subgroup; 1.580 days in the 81-85 
years old subgroup and 1.727 days for those 
over 85 years old evaluated. 
The average time of hospitalization was 
10.118 days (+/- 7.913) for the 75-80 years 
old subgroup; 11.709 days (+/- 8.327) for the 
81-85 years old subgroup and 69.909 days (+/- 
6.786) for those over 85 years old. 
There are no significant differences 
between the 3 subgroups regarding the average 
time of hospitalization. 
As for the topography of the CSH in 
relation with antithrombotics the study found 
that the prevalence of those over 75 was higher 
(19.35%) in the anticoagulated group vs. 
12.50% in those who did not benefit from the 
treatment and the same in the under 75 years 
old group where 22.72% had antithrombotics 
vs 15.65% without treatment. 
Regarding the prevalence of comorbidity in 
the study, high blood pressure with a total 
percentage of 49.568% and in those over 75 
years old - 55.789% and below 75 years old-
45.255%; followed by ischemic cardiopathy 
GCS Total Patients over 75 Patients under 75 
13-15 5.263% 9.589% 2.564% 
9-12 30% 45.454% 11.111% 
GCS=8 38% 60% 0% 
GCS=6-7 
 
0% 0% 
 
0% 
GCS=4-5 
 
60% 66.666% 
 
50% 
GCS=3 33.333% 50% 25% 
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showing a total of 19.396%, atrial fibrillation 
comes third in line, followed by stroke, 
diabetes and others. 
Discussion 
The study found —that under several 
aspects— significative differences concerning 
the evolution of a chronic subdural 
haematoma in the population under and over 
75 years old. The haematomas are frequently 
encountered in the male population evenly 
under and over the age of 75, thus the total 
number of deaths are often seen in those over 
75 no matter of gender or topography affected 
by the pathology. 
The state of coma was attributed more to 
those over 75. The administration of 
antithrombotics was a direct factor of 
correlation for the apparition and recurrence 
of the haematoma and presented higher 
incidence rates of bilateral CSH with respect to 
Edlmann E et al. [9] and De Bonis P. et al. [7]. 
The elder patients seemed to have a lower rate 
of favorable neurological outcomes after the 
treatment opposite those of younger ages. The 
mortality is greater in the male population, 
and the study shows the appearance of motor 
deficits and aphasia were frequently seen in 
those under 75 years old in contrast with 
convulsions and the Babinski signs that 
predominate in those over 75 years old. 
Midline shift as a contributory factor of 
mortality was on all of its deviations and levels 
predominantly seen in the over 75 years group 
and less in those younger, and also 
independently of the GCS at admission with 
reference to Kim HC et al. [17]. There were no 
differences in the matter of mortality for those 
who had bilateral haematomas in respect of 
the general CSH prevalence. 
Those treated conservatively from the 
group over 75 years old had a lower 
improvement percentage, higher mortality 
and stationary neurological outcome than the 
younger ages [35]. 
In a 2015 study, Aristedis Rovlias, Spyridon 
Theodoropoulos and Dimitrios 
Papoutsaki[26] reported a direct correlation 
between the CSH prognostic and the 
neurology status at admission, an aspect that is 
strengthened by this study observing the 
increasing mortality in parallel with a lower 
GCS, therefore at a GCS between 13-15, 
mortality was 5.26%, at a GCS of 9-12 the 
mortality was 30%, at GCS 8 and 4-5 mortality 
was 37.5% and 60% respectively. 
Masaaki Uno et al. [31] focused in an article 
over the less favorable outcome of the CSH in 
patients over 75 years old vs. those under 75, as 
did this study that showed a higher mortality 
among those over 75 (18.9%) than in those 
under 75 (4.3%), and lower favorable outcomes 
for elderly patients (75.7%) vs younger ages 
(86.8%). 
Antithrombotic usage represents an 
independent rise factor for the appearance of 
the CSH and it can also influence the prognosis 
[32,33,27]. In this study, 32.6% of those in the 
over 75 years old group had antithrombotics in 
comparison with 16% of those in the younger 
group. 
In a study made by Agawa et al. [1], he 
reported a more unfavorable outcome for those 
with bilateral CSH, a fact that this study also 
confirmed, that mortality from bilateral CSH 
was significantly higher in patients over 75. 
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Regarding the surgical treatment of the 
CSH, Masaaki et al.[31] presented a favorable 
outcome for those treated by surgery of 
between 70-90%, also demonstrated by this 
study in terms of neurological improvement 
(83.2%), even if the prognostic worsened for 
those over 80 than under, this aspect 
determined the making of age-related 
subgroups and showed that in those over 85 
the mortality reduced by half. 
In-hospital related mortality in this study 
stands at the limits somewhere at 10.3% in 
comparison to Masaaki with reported limits 
between 0.21%-27.5%. 
In a 2012 study on 125 patients made by 
Danilo Otavio de Araujo Silva et al. [6] with 
CSH, headaches showed in 40% of patients 
and deficits at 44%. This study percentage is 
nearby those values with 56.8% for the first one 
and 57.7% for the deficit. 
I. A. Iliescu [11,12], in an article, correlates 
the higher incidence of the CSH in the male 
population, also demonstrated by this study. 
From the total of 232 patients,181 were male 
(78%) and only 51 were female (22%), and 
apparently the male gender is an independent 
negative factor for the CSH outcome, 
mortality being significative higher than in the 
female population (8.6% vs 1.7%). The same 
study reports a more right cerebral 
hemisphere dominance of the CSH (52%) and 
only 30% affecting the left side, therefore, in 
comparison this study found a more left-side 
prevalence of the CSH despite the 2 categories 
and last but not least between 2-19% of the 
patients had convulsions in the comparative 
study, in this study it was found that 9.05% of 
patients were affected which resemble the 
study of Battaglia et al.[4] who reports 
incidences of 10.6% and 14.9%. 
Quiang-Ping Wang et al. [33] exemplified 
in a study that from their cohort of CSH- 
presenting patients, 20.5% had high blood 
pressure, 16.6% had heart failure and 13.9% 
had diabetes. In this study the findings were in 
the order 49.5%,11.6% and 16.3% thus high 
blood pressure and heart failure were found 
more often in those over 75 years old. 
Borger V. et al. [5] randomized patients in 
3 age-related groups as follows: 65-74 years; 
75-84 years and 85-94 years. They concluded 
that postoperative although all the groups had 
increased improvement scores, they 
synchronized with age. Our study has similar 
results, therefore in those treated under 75 the 
percentage was 86.8% and declining to 75.7% 
in those over 75. 
In this study, 3.01% of patients showed a 
positive diagnosis for cancer, higher for those 
over 75 years old and it correlates with the 
study of Yuji Agawa et al. [1] that stated an 
unfavorable prognostic for those affected by a 
tumor. 
Conclusions 
There are significant differences between 
the CSH outcome in the two study 
populations, therefore we consider that those 
differences should be taken into consideration 
for the in-hospital care of patients in order to 
maximize the prognostic. 
Patients over 75 years old are posing a 
higher mortality rate than the younger ages. 
Coma is a complication of the slower rates of 
improvement, convulsions and deficits in the 
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group over 75 do not contraindicate surgery 
when imposed. 
Those on antithrombotics showed an 
increased risk of developing bilateral CSH at 
higher ages and a more unfavorable outcome, 
a fact that is also predicted by the value of the 
MLS or the associated comorbidities, making 
the approach more complex. 
The aging process will eventually lead to a 
higher incidence and prevalence of CSH in the 
population and can also stimulate the necessity 
of permanent care and evaluation of these 
kinds of patients. 
There is a need for supplementary studies 
and opinions in order to establish a common 
point of optimum treatment of this vulnerable 
category of patients. 
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